Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ramsey Baghdadi
Former HHS No. 2 would bring extensive knowledge of the sprawling department and policy expertise in the drug pricing area, where the Trump Administration is readying new actions.
Safety notice for Merck's Keytruda in multiple myeloma had some notable elements – from what comes next to who delivered the message.
US FDA’s top cancer drug reviewer has been uncharacteristically quiet during recent advisory committee meetings. That just changed, and the result may not have been great for the sponsor (Pfizer), but it is a reminder of the value that Pazdur’s institutional knowledge and outspokenness bring to all of FDA.
Conflict of interest waivers for US FDA advisory committee review of sunitinib's supplemental application signal that difference in statistical analyses for disease-free survival could be key area of discussion.
The White House missed an opportunity to tout a major legislative accomplishment in the first year of President Trump’s term.
Sponsors are seeking US “Breakthrough Therapy” Designations at a record pace in FY 2017.